Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, pr
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... 21, 2011 United Therapeutics Corporation (Nasdaq: ... its FREEDOM-C(2) registration trial was completed on March ... multi-center, international, double-blind, randomized, placebo-controlled study of a ... in pulmonary arterial hypertension (PAH) patients receiving an ...
... Paul Braun,s lab look like any others, but they ... three-dimensional nanostructure for battery cathodes that allows for dramatically ... The researchers, findings will be published in the March ... Nanotechnology. Aside from quick-charge consumer electronics, batteries ...
... 18, 2011 Driving value for customers is critical to ... points between a customer and an organization, there has to ... an organization to succeed in the marketplace. ... Practices, LLC., noted in this month,s special issue of PharmaVoice ...
Cached Biology Technology:United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Batteries charge quickly and retain capacity, thanks to new structure 2Batteries charge quickly and retain capacity, thanks to new structure 3Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2
... July 14, 2009 NYU and NYU School of ... Award from the National Institutes of Health (NIH) to establish ... with the New York City Health and Hospitals Corporation (HHC). ... rapidly advance science from the lab to the patient to ...
... French cave of Arago, an international team of scientists has analyzed ... Homo heidelbergensis . It is the first time that an ... occupations at archaeological sites. The key is the last food that ... of the groups of hominids and how long they spent in ...
... Nanyang Technological University (NTU),s Assistant Professor Li Hoi Yeung, ... made an important contribution to the understanding of the ... process known as ,apoptosis, or programmed cell death, is ... perhaps a million cells a second. According to ...
Cached Biology News:$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 2$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 3$29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation 4The last supper of the hominids establishes the times they lived at the sites 2Study by NTU professors provides important insight into apoptosis or programmed cell death 2
... platform for fully automated systems for a ... be configured for applications ranging from compound ... closed loop screening, which means it has ... cherry picking and follow up studies all ...
... are disposable microfiltration devices for the fast and ... 100 l to 500 l. They can be ... centrifuge tubes. Product Features: High-flux Polyethersulphonemembrane ... Low hold up volume ( Fast and reproducible ...
... Caliper Prelude Workstation fully automates pharmaceutical ... addition, extraction, sample transfer, mixing and ... and UV detection. The Prelude performs ... 21 CFR Part 11. The ...
... any standard fixed-angle microcentrifuge rotor at ... centrifuge tube filters consist of a ... tube. They filter by centrifugation for ... preparation, removal of cells from media ...
Biology Products: